ArticleAsia-Pacific journal of clinical oncology2025
Neoadjuvant Chemotherapy With Chemoradiotherapy for Patients With Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma-Retrospective Review From a Tertiary Care Hospital.
Article in Asia-Pacific journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Review
- CKAAKN peptide-conjugated long-circulating nanoliposomes for the targeted delivery of oridonin to pancreatic cancers.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimPatients diagnosed with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) have historically worse survival rates compared to those with resectable pancreatic cancer. The study aimed to assess the feasibility and efficacy of neoadjuvant chemotherapy and chemoradiotherapy in BRPC/LAPC. Additionally, we evaluated the R0 resection rates for patients who progressed to surgery.
methodsThis retrospective study included patients diagnosed with BRPC/LAPC between January 2019 and December 2023 at The Canberra Hospital (TCH), a tertiary care setting. A total of 115 patients were screened, of whom 37 were eligible for inclusion. Demographic data, CA19-9 levels, treatment regimens, surgical outcomes, resection rates, disease-free survival (DFS), and overall survival were analysed.
resultsA total of 20 (54%) patients (15 FOLFIRINOX and 5 gemcitabine/nab-paclitaxel) completed their planned chemotherapy, and 17 (46%) of these patients had chemoradiotherapy, majority receiving 45-50 Gy of conventional radiation with capecitabine. Tumor marker Ca19-9 normalized after chemotherapy in seven patients (19%). In total, 23 patients (62.2%) progressed to surgery. The median DFS for all patients was 12.7 months (95% CI 5.5-15.9), and the median OS was 21 months (95% CI 13.7-44.9).
conclusionThis study suggests that neoadjuvant treatment is feasible for BRPC/LAPC, allowing patients to undergo surgery and achieve R0 resection. However, further randomized controlled trials with larger cohorts are needed to validate these findings and refine treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.